Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Completes $39M Financing amid IPO Plans

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Complete Genomics today announced that it has closed a Series E round of financing, raising proceeds of $39 million.

Less than a month ago, the Mountain View, Calif.-based sequencing services firm filed for an initial public offering in the US, with plans to raise as much as $86.3 million. In the preliminary prospectus for the offering, Complete Genomics said that it would use proceeds from the offering to finance further development and commercialization of its technology, sales and marketing activities, capital expenditures to expand its facilities and operations, and working capital and other general corporate purposes.

The Series E round of financing was led by Sands Capital, a new investor in the firm. Existing investors including Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital Management, and Enterprise Partners.

In addition to announcing the financing, Complete Genomics also said that it is evaluating a recent lawsuit filed against the firm by Illumina for alleged patent infringement. Illumina filed the suit two weeks ago, claiming that Complete Genomics' sequencing platform and services infringe US Patent Nos. 6,306,597; 7,232,656; and 7,598,035. The patents cover DNA sequencing by parallel oligonucleotide extensions, the use of arrayed biomolecules in sequencing, and methods and compositions for ordering restriction fragments.

"We cannot guarantee any particular outcome, as with any litigation, but we believe that we have substantial and meritorious defenses to the claims and intend to vigorously defend against this lawsuit," Complete Genomics Chairman, President, and CEO Cliff Reid said in a statement.

He noted that two of the patents have been put into re-examination at the US Patent Office, and all of the claims have been initially rejected and await further review. In addition, he said that the third patent had been subject to re-examination. Though the USPTO upheld the validity of an independent method claim in that patent, a Federal Circuit subsequently affirmed a District Court Order that the independent method claim in that patent is invalid under the District Court's claim construction, Reid added.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.